Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Defoslimod SCHEMBL13752580 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL13231311 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| SCHEMBL8209575 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL3714038 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL12469694 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL13705691 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| SCHEMBL8208245 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL13744280 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| Defoslimod SCHEMBL19839002 | 1.00 | TLR4 (0.75) | TLR4LY96 | |
| SCHEMBL8209574 | 1.00 | TLR4 (0.75) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097237-A2 | CYTOSOLIC BACTERIAL PATHOGENS ATTENUATED FOR SPREAD FROM TUMORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| CN-115792075-A | Detection method of 4' -monophosphoryl lipid A compound | 江苏瑞科生物技术股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-9592282-B2 | Vaccines for malaria | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-03-14 | — | — | US | claimed |
| EP-2040742-B1 | VACCINES FOR MALARIA | GLAXOSMITHKLINE BIOLOG SA (BE) | 2014-10-29 | — | — | EP | claimed |
| US-20100150998-A1 | VACCINES FOR MALARIA | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2010-06-17 | — | — | US | claimed |
| US-20100062028-A1 | VACCINES FOR MALARIA | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2010-03-11 | — | — | US | claimed |
| EP-2040742-A2 | VACCINES FOR MALARIA | GlaxoSmithKline Biologicals S.A. (BE) | 2009-04-01 | — | — | EP | claimed |
| EP-2040743-A2 | VACCINES FOR MALARIA | GlaxoSmithKline Biologicals S.A. (BE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008009650-A2 | VACCINES FOR MALARIA | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2008-01-24 | — | — | WO | claimed |
| WO-2008009652-A2 | VACCINES FOR MALARIA | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2008-01-24 | — | — | WO | claimed |
| US-12616743-B2 | Streptococcal GlcNAc-lacking glycopolypeptides, cell wall carbohydrates, streptococcus vaccines, and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2026-04-23 | — | — | US | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-4709423-A1 | NOVEL CANCER TREATMENTS WITH IL-2 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2026-03-18 | — | — | EP | disclosed |
| US-20260034168-A1 | NANOPARTICLE CONSTRUCTS FOR SYSTEMIC CO-DELIVERY OF ANTI-TUMOR AGENTS | UNIV CASE WESTERN RESERVE (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2005117958-A1 | VACCINE COMPOSITIONS COMPRISING VIROSOMES AND A SAPONIN ADJUVANT | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005112991-A2 | VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113756-A1 | METHOD | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2005-12-01 | — | — | WO | disclosed |
| EP-0729473-B1 | GLUCOSAMINE DISACCHARIDES, METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND THEIR USE | OM PHARMA (CH) | 2000-08-23 | — | — | EP | disclosed |
| US-6005099-A | FOR IMMUNOMODULATORS, ANTITUMOR AGENTS, AND COMPONENTS OF VACCINES WITH REDUCED ENDOTOXICITY | LABORATOIRES OM S.A. (CH) | 1999-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | IL2, IL2RA, ILF2 | TLR4 1381/4885LY96 50/4885 |
| US-12616743-B2 | Streptococcal GlcNAc-lacking glycopolypeptides, cell wall carbohydrates, streptococcus vaccines, and methods for making and using them | PGLS, ST3GAL3, FUT5 | TLR4 673/4885LY96 131/4885 |
| US-20260034168-A1 | NANOPARTICLE CONSTRUCTS FOR SYSTEMIC CO-DELIVERY OF ANTI-TUMOR AGENTS | STING1, TLR9, TLR1 | TLR4 4/4885LY96 30/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | TLR4 1332/4885LY96 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.